Table 1 Comparison of UPRmt between cancer cells and normal cells
From: Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor
| Â | UPRmt in cancer cells | UPRmt in normal cells |
|---|---|---|
Cell type | All type of the carcinoma cells | Post-mitotic cells |
Activitor | Accumulation unfolded proteins, impaired ETC, mtdna mutation and deletion, inhibition of mitochondrial chaperones or proteases, increased ROS level | Accumulation unfolded proteins, impaired ETC, mtDNA mutation and deletion, inhibition of mitochondrial chaperones or proteases, increased ROS level |
Regulatory pathway | CHOP-, SIR3/7-, Pink-, Nrf-, calcium-, and ATF4/5-mediated signal pathway | SIR3/7-, and ATF4/5-mediated signal pathway |
Effector | FOXOs, HSPs, HIF, ClpP, SOD1/2, MAPK, OXPHOS-related proteins, proteasome, mitochondrial ribosomal protein | HSPs, SOD1/2, OXPHOS-related proteins, proteasome |
Outcome | Cancer proliferation and metastasis | Cell longevity and lifespan extension |